miRecule Names J&J Pharma Vet Fu-An Kang to Lead Growing Research Team!
Accomplished Drug Hunter named VP of Research – miRecule.com
miRecule Closes $5.7M to Create RNA Therapies for Cancer and Muscular Dystrophy!
Important Milestone In Pursuit Of Improved Therapeutic Outcomes For Patients – Intrado
miRecule’s Charles Marusak to present at Friends of FSH Research 2021!
Annual Meeting Highlights The Latest Cutting-Edge Research Against FSHD – Friends of FSH Research 2021
miRecule adds Maryland Momentum Fund to its Seed Round!
USM Maryland Momentum Fund Invests $250,000 in $3.5M Seed Round of miRecule Inc. – USM Momentum Fund
miRecule awarded grant by Friends of FSH Research!
Antisense Oligonucleotide-Antibody Conjugates to Treat FSHD – Friends of FSH Research
miRecule featured by the FSHD Society!
miRecule, Inc., is developing a novel treatment for FSHD – FSHD Society
miRecule featured by the BioHealth Capital Region Investment Conference!
miRecule closes Seed Round at the second annual BioHealth Capital Region Investment Conference – BioBuzz
miRecule published in Clinical Cancer Research!
Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer – Clinical Cancer Research
miRecule interviewed in the Washington Business Journal!
Anthony Saleh’s biotech, miRecule, is using microRNA therapeutics to treat cancers. This seed round will send the startup into the next phase of its journey toward clinical trials. – Washington Business Journal